Rollover trial for people already on Roche study treatment
Part of Cancer clinical trials.
This is a “rollover” study for people who were already taking a Roche (or Genentech) cancer study medicine. It checks whether continuing the same study treatment (when commercial options aren’t available) can keep helping you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were already in a Roche/Genentech-sponsored study using the study medicine (IMP) or its comparison drug
- Your parent-study plan allows you to keep taking the study treatment or its comparator when rolling over
- Your first dose in this extension must start within 7 days of the approved treatment gap from the parent study
- The study doctor feels you are still benefiting from the study treatment or comparator at rollover
- You can follow the rules and visits for this extension study
- You do NOT have an active serious issue from the parent study that hasn’t returned to near-normal levels (baseline) or only mild level
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial lets people who were already in a related “parent” study either keep taking treatment or restart it after it had stopped working for a while. It’s meant for people who previously had a meaningful response and may still benefit from continued treatment.
This study lets people who were in an earlier Exelixis cancer treatment trial continue receiving the same treatment if it's still helping them. It's designed to see how safe and effective the treatment is over a longer period.
This trial tests whether giving immunotherapy again can help people with solid tumors who have already tried an experimental treatment in a clinical trial and it stopped working. It looks for patients whose cancer has returned or spread and who can start the new treatment within 12 weeks of their last therapy.
This trial is for people who are already in a RVU120 study and have been receiving the drug for at least 5 cycles. It allows you to keep getting RVU120 if you are benefiting from it and don't have other treatment options.
This trial is for people who are already being treated with ONO-4538 (either alone or with other treatments) and can continue into an “extension/rollover” study. It checks how well ONO-4538 continues to work and is used safely over more time.
This study is for people who have already taken the study drug povorcitinib in a previous trial and found it helpful. It lets you continue receiving the treatment and allows doctors to keep tracking its long-term safety and effects.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.